Table 2.
MET exon 14 skipping variants targeted therapy outcomes in advanced NSCLC.
| Study group | Type of cancer | Drug | Stage | Study phase | No. of patients | Assay used | ORR | Median PFS in months (95% CI) |
|---|---|---|---|---|---|---|---|---|
| Drilon et al. 44 | NSCLC | Crizotinib (9% PSCs) | Advanced | I | 69 | NGS, RT-PCR | Overall: 32% (21/65) ORR by alteration type: Indels: 25% (5/20). Point mutations: 36% (12/33). Splice acceptor site mutations: 31% (5/16). Splice donor site mutations: 32% (12/37). |
7.3 (5.4–9.1). |
| Moro-Sibilot et al. 45 | Crizotinib (PSCs% unknown) | Advanced | II | 28 | NGS and Sanger sequencing | ORR: 10.7% | 3.6 (1.6–7.1) | |
| Wolf et al. 35 | Capmatinib (INC280) (none-PSCs) |
Advanced | II | Pretreated: 100 treatment naive: 60 | RT-PCR, NGS | Pretreated: 44%, treatment naive: 68.3% | Pretreated: 5.5 (4.2–8.1) Treatment naive: 12.5 (8.3–18.0) |
|
| Mazieres et al. 39 | Tepotinib (PSCs% unknown) | Advanced | II | Overall: 313 Pretreated: 149 Treatment naive: 164 |
RNA-based NGS | Overall: 51.4% Pretreated: 45%, Treatment naive: 57.3% |
Overall: 11.2 (9.5–13.8) Pretreated: 11.0 (8.2–13.7), Treatment naive: 12.6 (9.7–17.7) |
|
| Lu et al. 46 | PSCs and other NSCLCs | Savolitinib (36% PSCs) | Advanced | II | PSCs: 25, non-PSCs: 45 | Sanger DNA sequencing or DNA-based NGS | TRES (tumor response evaluable set): ORR: 53.2% PSCs: 50%, other NSCLCs Non-PSCs: 55% |
Overall: 6.9 (4.6–8.3) PSCs: 5.5 (2.6–6.9), Other NSCLCs (non-PSCs): 7.0 (5.5–13.7) |
| Yu et al. 38 | NSCLC | Glumetinib (6% PSCs) | Advanced | II | Overall: 84 Pretreated: 38 Treatment-naive: 46 |
RNA-based RT-PCR | Overall: 66% Pretreated: 60% Treatment-naive: 71% |
Overall: 8.5 (7.6–9.7) Pretreated: 7.6 (4.1–9.6), Treatment-naive: 11.7 (7.6–21.9) |
| Lu et al. 42 | Savolitinib (8% PSCs) |
Advanced | IIIB | 87 (Treatment naive) |
NA | ORR: 58.6% | 13.8 (9.7, NR) |
mPFS, median progression free survival; NGS, next-generation sequencing; NR, not reached; NSCLC, non-small-cell lung cancer; ORR, overall response rate; PFS, progression-free survival; PSCs, pulmonary sarcomatoid carcinomas; RT-PCR, reverse transcription polymerase chain reaction.